• COVID-19
  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • Artificial Intelligence
    • Blockchain
    • Mobile Health
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage

FDA Extends RCA With COTA to Explore COVID’s Effect on Cancer

by Fred Pennic 11/04/2020 Leave a Comment

What You Should Know:

– The FDA just extended its research collaboration agreement (RCA) with COTA, specifically looking at how COVID-19 is affecting cancer.

– With this expanded agreement, COTA and the FDA will use real-world data to explore the impact of COVID-19 and the pandemic on cancer treatment, with the opportunity to expand into other oncology questions in the future.


COTA, Inc., a healthcare technology company that uses real-world data to bring clarity to cancer care, today announced it has extended its Research Collaboration Agreement (RCA) with the U.S. Food and Drug Administration (FDA) for an additional three years. This renewed RCA will expand on the objective to explore the applications of real-world data in oncology, including the impact of COVID-19 and the pandemic on cancer treatment. As the project advances, the research will broaden to study other oncology care delivery questions.

Real-world data can provide critical insights into the delivery of cancer treatment in the routine practice setting, as well as potential long-term effects post-COVID-19 recovery. The expanded focus of this RCA will enable the exploration of important research questions to help support FDA’s understanding of how the COVID-19 pandemic continues to impact patients with cancer.

Why It Matters

With over 8 million cases of COVID-19 in the United States, there is a significant need to understand the pandemic’s impact on oncology care. Additionally, an increasing body of research has shown that oncology patients may be particularly susceptible to harm during this pandemic – both in contracting the condition itself or experiencing care delays.

Cancer patients are particularly at risk of severe complications with COVID-19, and there is currently no understanding of how this can affect their oncology care or progression. Through real-world data, we can begin to understand if COVID-19 should be considered as comorbidity – particularly around clinical trial criteria.

RELATED:   Why A Patient-First Strategy for Specialty Rx Pharmacists Is Critical to Optimize Outcomes

Tagged With: cancer, Clinical Trial, Coronavirus (COVID-19), COTA, FDA, healthcare technology, Oncology, risk

[ultimatesocial networks="facebook,twitter,google,linkedin,mail" url="" custom_class="us-posts-bottom" align="left" count="false"]

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

« MIT’s Algorithm Reduces Unnecessary Use of Antibiotics for UTIs
How RPA Can Help Get COVID-19 Vaccines to High-Risk Patients First »

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Recent Articles

  • To Beat COVID-19, We Need A Modern Approach to Public Health Data

    To Beat COVID-19, We Need A Modern Approach to Public Health Data

    ... more
  • HealthStream Acquires Policy Management System ComplyALIGN for $2M

    HealthStream Acquires Policy Management System ComplyALIGN for $2M

    ... more
  • Technologies That Are Transforming the Nursing Profession

    4 Technologies That Are Transforming the Nursing Profession

    ... more
  • mPulse Mobile Acquires Digital Health Engagement Company Big Know

    mPulse Mobile Acquires Digital Health Engagement Company The Big Know

    ... more

Most Read

  • CVS Health Launches Senior Medical Alert System, Symphony CVS Health Launches Senior Medical Alert System, Symphony
  • Philips Acquires Medical Device Integration Platform Capsule for $635M Philips Acquires Medical Device Integration Platform Capsule for $635M
  • 30 Executives Share Top Healthcare Predictions & Trends to Watch in 2021 30 Executives Share Top Healthcare Predictions & Trends to Watch in 2021
  • Job Titles for Healthcare Executives The Top 9 Most In-Demand Medical Jobs
  • 16 COVID-19 Predictions and Trends for 2021 Executive Roundup 12-Available-COVID-19-Vaccine-Management-Solutions-to-Know-In-Depth-1 20 Recently Launched COVID-19 Vaccine Management Solutions to Know
  • DPHO, UnitedHealthcare Launch Accountable Care Program UnitedHealth Rolls Out Employer Virtual Primary Care Plan
  • 3 Steps to Maintain Telehealth’s Momentum Post-Pandemic 3 Steps to Maintain Telehealth’s Momentum Post-Pandemic
  • FCC COVID-19 Telehealth Program Providers FCC Unveils 14 Initial Projects Selected for $100M Connected Care Pilot Program
  • 20 COVID-19 Predictions and Trends for 2021 - Executive Roundup 20 COVID-19 Predictions and Trends for 2021 – Executive Roundup
  • Fundamental Surgery Becomes First VR Surgical Training Simulation to Gain CPD Accreditation 18 Healthcare Augmented Reality and Virtual Reality Companies to Watch

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • 2020 Editorial Calendar
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2021. HIT Consultant Media. All Rights Reserved. Privacy Policy |